This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Managing risk is part of everyday business. But how do you deal with fear? Fear management has been a key challenge at Biogen Idec for the past four years, since a few patients taking the company’s ...

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...

In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...

The National Institute for Health and Care Excellence (NICE) has recommended natalizumab for treating adults with highly active relapsing-remitting multiple sclerosis (RRMS) whose disease has ...

FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the loss of patent protection for a ...